The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of combination therapy with anti-EGFR antibody as first-line treatment for RAS wild-type metastatic colorectal cancer according to anatomical tumor location from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
 
Kentaro Yamazaki
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Kenta Iguchi
No Relationships to Disclose
 
Toshihiro Misumi
Honoraria - Miyarisan pharmaceutical
Consulting or Advisory Role - Anaut Inc.
 
Hideaki Bando
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Eiji Oki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Guardant Health
 
Jean-Yves Douillard
No Relationships to Disclose
 
Miriam Koopman
No Relationships to Disclose
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; Agenus; ALX Oncology; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bexon Clinical Consulting; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Daiichi Sankyo; Debiopharm Group; Eisai; ElmediX; Fosum; Galapagos NV; GlaxoSmithKline; Ipsen; ITeos Therapeutics; Lilly; Merck KGaA; Merck Sharp & Dohme; Microbial Machines; Mirati Therapeutics; Nordic Group; Novartis; Novocure; Pfizer; Pierre Fabre; Sanofi; Seagen; SERVIER; Simcere; Taiho Pharmaceutical; Takeda; Trishula Therapeutics
 
Carsten Bokemeyer
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; I-Med Institute; Medupdate; Merck KGaA; Merck Sharp Dohme; Roche
Consulting or Advisory Role - AOK Health Insurance; Bayer Schering Pharma; Daiichi Sankyo Europe GmbH; Janssen-Cilag GmbH; Lindis Biotech; Merck Sharp & Dohme; Oncology Drug Consult (ODC); Sanofi
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Agile Therapeutics (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); Apellis Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BerGenBio (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CPT Cellex Patient Treatment (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Glycostem (Inst); Glycotope GmbH (Inst); immatics (Inst); Incyte (Inst); IO Biotech (Inst); Ipsen (Inst); Isofol Medical (Inst); Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Millennium (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Servier/Pfizer (Inst); Springworks Therapeutics (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Janssen-Cilag; Merck Serono; Sanofi
 
Alan Venook
Consulting or Advisory Role - Abbvie; Amgen; Eisai; Exact Sciences; Exelixis; INTERA; Pfizer
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
 
Yoshihiko Maehara
No Relationships to Disclose
 
Volker Heinemann
Stock and Other Ownership Interests - BioNTech SE
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Merck; MSD; Novartis; Oncosil; Pfizer; Pierre Fabre; Roche; Sanofi; Seagen; SERVIER; Sirtex Medical
Consulting or Advisory Role - Amgen; AstraZeneca; GlaxoSmithKline; Halozyme; Janssen; Merck; MSD; Nordic Bioscience; Oncosil; Pierre Fabre; Roche; Servier/Pfizer; TERUMO
Research Funding - Amgen (Inst); Merck (Inst); Roche (Inst); Servier (Inst)
Expert Testimony - Oncosil; Servier
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Merck; MSD; Nordic Bioscience
 
Chiara Cremolini
Honoraria - Amgen; Bayer; GlaxoSmithKline; Merck; Merck; MSD; Pierre Fabre; Roche; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Bayer; Bicara Therapeutics; MSD; Nordic Bioscience; Pierre Fabre; Revolution Medicines; Roche; Rottapharm Biotech; Takeda
Speakers' Bureau - Merck; MSD; Pierre Fabre; SERVIER
Research Funding - Bayer; Merck; Roche; SERVIER
 
Goro Nakayama
No Relationships to Disclose
 
Thierry Andre
Honoraria - Bristol-Myers Squibb; Merck; Merck Serono; Sanofi; Seagen; SERVIER
Consulting or Advisory Role - Abbvie; Aptitude Health; Aptitude Health; Bristol-Myers Squibb; Exelixis; Gilead Sciences; GlaxoSmithKline; Medicenna; MSD Oncology; Nimbus Therapeutics; Nordic Bioscience; Pfizer; Sanofi; Sanofi; Seagen; SERVIER; Takeda
Speakers' Bureau - Biocartis
Travel, Accommodations, Expenses - Bristol-Myers Squib; Bristol-Myers Squibb; Merck; MSD Oncology; Takeda
Other Relationship - Inspirna
(OPTIONAL) Uncompensated Relationships - Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group; ARCAD Foundation; ARCAD Foundation
 
Qian Shi
Consulting or Advisory Role - Abbvie; Agenus; BeOne Medicines; BMS; Exelixis; Genmab US, Inc; Hoosier Cancer Research Network; HopeAI, Inc; Mirati Therapeutics; Regeneron
Research Funding - BMS (Inst); Janssen (Inst); MPAACT (Inst); Novartis (Inst); Regeneron (Inst); Roche/Genentech (Inst)
 
Aimery De Gramont
No Relationships to Disclose
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Indivumed; Sumitomo Corp.
Research Funding - Bristol-Myers Squibb Japan (Inst); Caris MPI (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); Exact Sciences (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); Natera (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)